Schizophrenia News and Research RSS Feed - Schizophrenia News and Research

Schizophrenia is a chronic debilitating disorder which affects more than two million Americans, and millions more worldwide. While significant progress has been made in understanding the disease and developing treatments, there remains a significant unmet medical need. More than 50% of patients switch their medication in a given year due to either poor response or the experience of adverse events.
Genetics underpin bullying victimisation influence on paranoia

Genetics underpin bullying victimisation influence on paranoia

Bullying victimisation in childhood may indicate genetic risk for later psychosis, rather than being an environmental trigger, say UK researchers. [More]
Changing placebo response dilutes antipsychotic trial power

Changing placebo response dilutes antipsychotic trial power

Factors including patients’ expectations may underlie an increased placebo response in antipsychotic randomised controlled trials published since 1960, say researchers. [More]
Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros Corporation today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. [More]
Fatty fish intake appears to increase antidepressant response rates

Fatty fish intake appears to increase antidepressant response rates

Up to half of patients who suffer from depression (Major Depressive Disorder, or MDD) do not respond to treatment with SSRIs (Selective Serotonin Reuptake Inhibitors). Now a group of Dutch researchers have carried out a study which shows that increasing fatty fish intake appears to increase the response rate in patients who do not respond to antidepressants. [More]
Aspirin can improve efficacy of schizophrenia treatments

Aspirin can improve efficacy of schizophrenia treatments

A new study shows that some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments. This work is being presented at the European College of Neuropsychopharmacology conference in Berlin. [More]
People with severe mental illness use YouTube to provide, receive peer support

People with severe mental illness use YouTube to provide, receive peer support

People with severe mental illness such as schizophrenia, schizoaffective disorder or bipolar disorder use a popular social media website like YouTube to provide and receive naturally occurring peer support, Dartmouth researchers report in the journal PLOS ONE. [More]
Genome Canada awards $6M grant to CAMH and Assurex Health

Genome Canada awards $6M grant to CAMH and Assurex Health

Assurex Health and Canada's Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia. [More]
Study: More interventions needed for people with severe mental illnesses in criminal justice system

Study: More interventions needed for people with severe mental illnesses in criminal justice system

Responding to the large number of people with serious mental illnesses in the criminal justice system will require more than mental health services, according to a new report. [More]
Research on zebrafish helps identify cause of unknown genetic disorder

Research on zebrafish helps identify cause of unknown genetic disorder

Research in zebrafish has helped identify the cause of an unknown genetic disorder affecting a boy and two of his uncles, scientists report in an article published October 14 in the journal GENETICS. [More]
Cardiometabolic health intervention urged for schizophrenia patients

Cardiometabolic health intervention urged for schizophrenia patients

Research shows high cardiometabolic risk, particularly increased dyslipidaemia and smoking, but little related medical treatment in patients with first-episode schizophrenia. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
‘Priming’ may improve schizophrenia patients’ social skills

‘Priming’ may improve schizophrenia patients’ social skills

Study findings suggest that social priming can increase the use of nonverbal social behaviours in patients with schizophrenia. [More]
Grand Challenges Canada announces 11 seed grants to improve mental health in developing countries

Grand Challenges Canada announces 11 seed grants to improve mental health in developing countries

On the day the world is collectively raising awareness on mental health issues, Grand Challenges Canada, funded by the Government of Canada, announced new funding for 11 novel ideas to improve mental health in developing countries, one of the biggest unmet needs of our time. Seed grants of up to $270,000 are awarded to 11 innovators from Canada and low- and middle-income countries, totalling $2.9 million CAD. [More]
New research reveals innovative way to classify severity of stroke

New research reveals innovative way to classify severity of stroke

New research conducted at the Florida State University-based National High Magnetic Field Laboratory has revealed a new, innovative way to classify the severity of a stroke, aid in diagnosis and evaluate potential treatments. [More]
Higher doses of neuroleptics needed for pregnant women with psychiatric conditions

Higher doses of neuroleptics needed for pregnant women with psychiatric conditions

The new generation of neuroleptics for psychiatric conditions has the advantage over older medications of fewer adverse side effects. An investigation into their effectiveness in pregnant women has now discovered that higher doses are needed during pregnancy to maintain the desired effect. [More]
Complex associations underlie functional variance in schizophrenia

Complex associations underlie functional variance in schizophrenia

The complex associations between predictors and mediators of real-life functioning highlight the need for integrated and personalised treatment for patients with schizophrenia, say researchers in World Psychiatry. [More]
Two UCSD professors of psychiatry honored for schizophrenia research

Two UCSD professors of psychiatry honored for schizophrenia research

Two professors of psychiatry at University of California, San Diego School of Medicine have been honored by the New York City-based Brain & Behavior Research Foundation for their work studying the genetics, dysfunction and treatment of schizophrenia, a chronic and severe brain disorder affecting roughly 1 percent of the general population or approximately 3 million people. [More]
Schizophrenia and bipolar disorder share common pathophysiological features

Schizophrenia and bipolar disorder share common pathophysiological features

Schizophrenia and bipolar disorder both appear to be associated with dendritic spine loss in the brain, suggesting the two distinct disorders may share common pathophysiological features, write author Glenn T. Konopaske, M.D., and colleagues at McLean Hospital, Belmont, Mass., and Harvard Medical School, Boston. [More]

Brain structure changes differ between schizophrenia symptoms

The specific areas of the brain with reduced grey matter in patients with schizophrenia differ according to whether they have predominant positive, negative or disorganised symptoms, research suggests. [More]
Dendritic spine density also reduced in bipolar disorder

Dendritic spine density also reduced in bipolar disorder

Patients with bipolar disorder have significant dendritic spine loss in the dorsolateral prefrontal cortex, postmortem findings show. [More]